Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL603311 | 1.00 | HRH3 (0.51) | HRH3CYP3A4CYP2C9KCNH2ESR2 | |
| SCHEMBL31267768 | 0.92 | CA12 (0.47) | HRH3CYP3A4CYP2C9KCNH2MAPT | |
| SCHEMBL12835619 | 0.84 | ESR2 (0.47) | HRH3ESR2MAPTNPC1RAB9A | |
| SCHEMBL2586831 | 0.83 | NPC1 (0.54) | HRH3CYP3A4CYP2C9KCNH2MAPT | |
| SCHEMBL14190729 | 0.81 | HRH3 (0.49) | HRH3CYP3A4CYP2C9KCNH2ESR2 | |
| SCHEMBL14535130 | 0.80 | HRH3 (0.56) | HRH3CYP3A4CYP2C9KCNH2ESR2 | |
| SCHEMBL10619463 | 0.79 | CYP2C9 (0.49) | HRH3CYP2C9ESR2MAPTNPC1 | |
| SCHEMBL10619470 | 0.79 | CYP2C9 (0.49) | HRH3CYP2C9ESR2MAPTNPC1 | |
| SCHEMBL11838572 | 0.78 | HRH3 (0.55) | HRH3CYP3A4CYP2C9KCNH2ESR2 | |
| SCHEMBL3668450 | 0.78 | NPC1 (0.44) | MAPTNPC1RAB9ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391611-B1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2391611-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086551-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | WO | disclosed |
| EP-0983225-B1 | NEW POLYMERISABLE LIQUID CRYSTALLINE COMPOUNDS | ROLIC AG (CH) | 2003-12-17 | — | — | EP | disclosed |
| EP-1295863-A1 | Liquid crystalline \"laterally polymerizable\" compounds | Rolic AG (CH) | 2003-03-26 | — | — | EP | disclosed |
| US-6395351-B1 | MIXTURE; OPTICS | ROLIC AG (CH) | 2002-05-28 | — | — | US | disclosed |
| EP-0983225-A1 | NEW POLYMERISABLE LIQUID CRYSTALLINE COMPOUNDS | Rolic AG (CH) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052905-A1 | NEW POLYMERISABLE LIQUID CRYSTALLINE COMPOUNDS | ROLIC AG (CH) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | HRH3 555/4885CYP3A4 274/4885CYP2C9 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.